Stocklytics Platform
Asset logo for symbol NEO
NeoGenomics
NEO66
$14.86arrow_drop_up1.50%$0.22
Asset logo for symbol NEO
NEO66

$14.86

arrow_drop_up1.50%

Performance History

Chart placeholder
Key Stats
Open$14.56
Prev. Close$14.66
EPS-0.61
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range14.04
15.01
52 Week Range11.79
21.22
Ratios
EPS-0.61

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

About NeoGenomics (NEO)

NeoGenomics Inc (NEO) is a leading provider of cancer-focused genetic testing services, specializing in comprehensive oncology testing for healthcare providers and researchers worldwide. With a commitment to accuracy, reliability, and innovation, NeoGenomics offers a wide range of testing options, including molecular diagnostics, flow cytometry, immunohistochemistry, and cytogenetics. The company's cutting-edge laboratories utilize state-of-the-art technology and a team of highly skilled scientists to deliver accurate and timely results. NeoGenomics' mission is to improve patient care through the advancement of personalized medicine and targeted therapies.
As of the latest market data, NeoGenomics Inc (NEO) has a market capitalization of $X billion, making it one of the largest players in the genetic testing industry. The company's stock price history has been relatively stable, with gradual growth over the past few years. NeoGenomics Inc (NEO) is publicly traded under the ticker symbol NEO and is listed on the NYSE. The stock is currently trading within its 52-week range of $X to $X and has a daily trading volume of X shares. In comparison to its industry peers, NeoGenomics Inc (NEO) has demonstrated strong performance and is well-positioned for future growth.
Sector
Healthcare
Industry
Diagnostics & Research
CEO
Mr. Christopher Michael Smith BSc
Headquarters
Fort Myers
Employees
2100
Exchange
NASDAQ
add NeoGenomics  to watchlist

Keep an eye on NeoGenomics

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is NeoGenomics 's (NEO) price per share?

The current price per share for NeoGenomics (NEO) is $14.86. The stock has seen a price change of $0.22 recently, indicating a 1.5% change. This reflects the stock's recent market performance and investor sentiment.
help

What is the 52-week high and low for NeoGenomics (NEO)?

For NeoGenomics (NEO), the 52-week high is $21.22, which is 42.8% from the current price. The 52-week low is $11.79, the current price is 26.04% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.
help

Is NeoGenomics (NEO) a growth stock?

NeoGenomics (NEO) has shown an average price growth of 4.52% over the past three years. It has received a score of 33 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying NeoGenomics as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.
help

What is NeoGenomics (NEO) stock price performance year to date (YTD)?

As of the latest data, NeoGenomics (NEO) has a year-to-date price change of -9.83%. Over the past month, the stock has experienced a price change of -13.35%. Over the last three months, the change has been 13.87%. Over the past six months, the figure is -2.11%. Looking at a longer horizon, the five-year price change stands at -53.99%.
help

Is NeoGenomics (NEO) a profitable company?

NeoGenomics (NEO) has a net income of -$87.97M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 41.34% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -8.39% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at $591.64M, with a revenue growth rate of 16.07%, providing insight into the company's sales performance and growth. The gross profit is $244.6M. Operating income is noted at -$107.74M. Furthermore, the EBITDA is -$447K.
help

What is the market capitalization of NeoGenomics (NEO)?

NeoGenomics (NEO) has a market capitalization of $1.91B. The average daily trading volume is 14.83, indicating the stock's liquidity and investor engagement.

Take Your Investments to a Whole New Level